Middle-East and Africa Meglitinide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Middle-East and Africa Meglitinide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Middle-East and Africa Meglitinide Market is expected to register a CAGR greater than 4% over the forecast period.

COVID-19 and diabetes have a significant impact on public health in the Middle East and Africa, as well as elsewhere. Diabetes has been linked to an increased risk of fatal infections and severe infections in COVID-19 patients. Because diabetes is one of the most common health problems in the Middle East and Africa, the current study focused on understanding the epidemiology of COVID-19 in diabetics and the strategies put in place by governments to mitigate its impact. In light of the importance and necessity of the epidemic, countries in the Middle East and Africa have implemented a number of preventative and control measures.

Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels. The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

This is driving the demand for Meglitinides in Middle-East and Africa, thereby driving the market in focus during the forecast period.​

Key Market TrendsRising Diabetes Prevalence in Middle-East and Africa Region

Type 1 diabetes accounts for approximately 10% of diabetes cases in the Middle East and Africa, while Type 2 diabetes accounts for 90%. Type 1 diabetes patients must take insulin for the rest of their lives, while also eating a healthy diet and exercising regularly. Type 2 diabetes patients must eat healthily, stay physically active, and have regular blood glucose tests. They may also need to take oral medication and insulin to keep their blood glucose levels under control. Diabetes has many complications, including diabetic ketoacidosis and non-ketotic hyperosmolar coma. Heart disease, stroke, kidney failure, foot ulcers, and eye damage are all serious long-term complications. Despite extensive research on COVID-19, only a few Middle Eastern and African countries have focused on the epidemiology of COVID-19 among diabetic patients and its implications. We emphasise the critical importance of conducting a thorough study to fully understand COVID-19 and its relationship to diabetes in order to develop and implement evidence-based initiatives and policies in the Middle East and Africa.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Middle East and Africa Region.

Saudi Arabia is Expected to Dominate the Middle-East and Africa Meglitinides Market.

Diabetes is one of the mounting health problems the country is facing. Saudi is ranked among the top three in the Middle East and African countries with the highest prevalence of diabetes. The diabetes population in Saudi Arabia increased from 1.48 million in 2012 to 5.95 million in 2021 and is expected to reach more than 8 million by 2027. The type-1 diabetes population in the country is projected to reach more than 0.5 million by 2027 from 0.39 million in 2021.

Saudi Arabia is aiming to reduce the prevalence of the disease by 10% over the next decade. Several initiatives, including taxing sugary drinks, fitness initiatives, and focusing on preventative care, are being taken up by the government to stem the rising epidemic. The government’s focus on combating diabetes and the higher purchasing power of the people in the country may help the market for diabetes drugs, like insulin drugs, during the forecast period.

Meglitinides, for example, bind to the sulfonylurea receptor in beta cells (pancreatic insulin-producing cells), but at a different site than sulfonylureas. Meglitinides' interaction with the receptor is not as "tight" as that of sulfonylureas, resulting in a much shorter duration of action and a higher blood glucose level required before the drugs produce pancreatic insulin secretion. There are currently two meglitinides available in the Middle East and Africa region, repaglinide (Prandin) and nateglinide (Starlix). Both are approved for use in Type 2 diabetes patients, both alone and in combination with other oral diabetes medications. The main effect of meglitinides is to lower after-meal blood glucose levels, which results in a lower HbA1c (an indicator of blood glucose control over the previous 2–3 months).

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The Meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.